Durrieu G, Senard J M, Rascol O, Tran M A, Lataste X, Rascol A, Montastruc J L
Laboratoire de Pharmacologie Médicale et Clinique (INSERM U317), Toulouse, France.
Neurology. 1990 Apr;40(4):707-9. doi: 10.1212/wnl.40.4.707.
We found blood pressure (BP), heart rate (HR), plasma norepinephrine (NE), and epinephrine (E) levels in the lying and the standing positions to be similar in never-treated parkinsonian patients (stages 1 and 2) and age-matched controls. CY 208-243, a new centrally active D1 agonist, significantly decreased BP, HR, and NE (but not E) values in the lying position; it elicited orthostatic hypotension and blunted the rise in NE elicited by standing up. These results indicate that the early stages of Parkinson's disease are not accompanied by major changes in autonomic cardiovascular function and suggest the involvement of central D1-receptors in the control of sympathetic tone.
我们发现,未经治疗的帕金森病患者(1期和2期)和年龄匹配的对照组在卧位和立位时的血压(BP)、心率(HR)、血浆去甲肾上腺素(NE)和肾上腺素(E)水平相似。新型中枢活性D1激动剂CY 208-243可显著降低卧位时的BP、HR和NE(但不影响E)值;它引发体位性低血压,并减弱站立引起的NE升高。这些结果表明,帕金森病早期自主心血管功能无重大变化,并提示中枢D1受体参与交感神经张力的控制。